Two of the most common chemotherapy drugs — including the only drug known to cure testicular cancer — are in short supply. It means oncologists are having to ration drugs and tweak treatment plans.
BioMimetic Continues Trying for Augment Approval
Brentwood-based BioMimetic has filed yet another round of paperwork in hopes of gaining federal approval for its bone graft therapy, called Augmentin.
On Air - 90.3 WPLN-FM